Benzinga | Jun 22, 2021 10:53AM EDT

HTG Receives First Order For HTG Transcriptome Panel, Enters Two European EAP Agreements

* HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe.

* The company continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.

* Entering into additional EAP agreements allows for further studies, which HTG believes will validate its Transcriptome Panel's performance requirements.

* Price Action: HTGM shares are up 4.2% at $5.34 during the market session on the last check Tuesday.